Table 1:

Demographic information, clinical course, location of tumor, radiation dose, time between SRS and follow-up imaging, biopsy results, and imaging results of each patient^a

Pt	Age (yr)	Clinical Course	Location	SRS Dose	SRS to Imaging	Bx	PET	SPECT	MR ASL
1	69	RCC, s/p SRS and stent, new CE	Left paraventricular	22 Gy × 1	11 Mo	RN	Negative	Positive	Negative
2	63	NSCLC, s/p SRS, new CE	Right frontal	19 Gy × 1	12 Mo	TP	SUV 20	Positive	Positive
3	79	NSCLC, s/p SRS, neurologic deterioration	Right frontal	22 Gy × 1	8 Mo	RN	SUV 4.9	Negative	Negative
4	64	Esophageal cancer, s/p SRS, new CE	Left frontal	21 Gy × 1	4 Mo	TP	Negative	Positive	Positive
5	72	SCLC, 3 lesions s/p WBRT + SRS	Left parietal	22 Gy × 1	7 Mo	TP	SUV 10.3	Positive	Positive
6	46	Breast cancer, s/p SRS, new CE	Right cerebellar	22 Gy × 1	4 Mo	TP	SUV 6.6	Negative	Positive
7	65	Melanoma, s/p SRS, neurologic decline	Right temporal	18 Gy × 1	10 Mo	RN	SUV 7.2	Positive	Negative
8	63	RCC, s/p SRS, new CE	Right thalamus	16 Gy × 1	6 Mo	RN	Negative	Negative	Negative
9	58	Melanoma, s/p IR, enlarged CE	Right frontal	19 Gy × 1	4 Mo	TP	SUV 10.7	Negative	Negative
10	52	NSCLC, s/p SRS, new CE	Right cerebellar	18 Gy × 1	3 Mo	RN	Negative	Positive	Negative
11	59	Melanoma, s/p SRS	Left frontal	22 Gy × 1	3 Mo	TP	SUV 8	Negative	Positive
12	52	Breast cancer, s/p SRS	Right temporal	8 Gy × 3	11 Mo	RN	Negative	Negative	Negative
13	56	RCC, s/p SRS	Left temporal	21 Gy × 1	12 Mo	RN	Negative	Negative	Negative
14	49	Melanoma, s/p SRS	Right frontal	21 Gy × 1	8 Mo	RN	Negative	Negative	Negative

Note:—RCC indicates renal cell carcinoma; Bx, biopsy; s/p, status-pos; IR, ionizing radiation; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; WBRT, whole brain radiation therapy.

^aPatients 1, 6, and 9 are those featured in the illustrative cases. Cells next to patients 1, 3, 7, 8, 10, and 12–14 represent RN on biopsy; other cells represent TN.